Overview

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Sutro Biopharma, Inc.
Treatments:
Antibodies
Immunoglobulins